MicroRNA profiling identifies miR-7-5p and miR-26b-5p as differentially expressed in hypertensive patients with left ventricular hypertrophy

Abstract

Recent evidence suggests that cell-derived circulating miRNAs may serve as biomarkers of cardiovascular diseases. However, a few studies have investigated the potential of circulating miRNAs as biomarkers for left ventricular hypertrophy (LVH). In this study, we aimed to characterize the miRNA profiles that could distinguish hypertensive patients with LHV, hypertensive patients without LVH and control subjects, and identify potential miRNAs as biomarkers of LVH. LVH was defined by left ventricular mass indexed to body surface area >125 g/m2 in men and >110 g/m2 in women and patients were classified as hypertensive when presenting a systolic blood pressure of 140 mmHg or more, or a diastolic blood pressure of 90 mmHg or more. We employed miRNA PCR array to screen serum miRNAs profiles of patients with LVH, essential hypertension and healthy subjects. We identified 75 differentially expressed miRNAs, including 49 upregulated miRNAs and 26 downregulated miRNAs between LVH and control patients. We chose 2 miRNAs with significant differences for further testing in 59 patients. RT-PCR analysis of serum samples confirmed that miR-7-5p and miR-26b-5p were upregulated in the serum of LVH hypertensive patients compared with healthy subjects. Our findings suggest that these miRNAs may play a role in the pathogenesis of hypertensive LVH and may represent novel biomarkers for this disease.

Circulating microRNA expression profiling and bioinformatics analysis of patients with coronary artery disease by RNA sequencing

“…These results show that miR‐22‐3p may contain important information on the onset, progression, prognosis, and other aspects in patients with cardiovascular disease. A previous study indicated that miR‐26b‐5p was upregulated in the serum of left ventricular hypertrophy (LVH) hypertensive patients compared with healthy controls . In our research, circulating miR‐26b‐5p was significantly upregulated in CAD patients.…”

The regulatory role of microRNAs in angiogenesis‐related diseases

“…However, levels of miR‐9 and miR‐126 in peripheral blood mononuclear cells (PBMCs) of hypertensive patients are reduced compared with healthy controls 178. Functionally, miR‐7‐5p can repress EC proliferation and angiogenesis by targeting RAF1,176 and let‐7 can induce oxidative stress and cell injury,177 suggesting that the up‐regulation of let‐7 may aggravate atherosclerosis, thereby modulating hypertension. In addition, miR‐9 can inhibit myocardin expression, and miR‐9 mimic can reverse the hypertrophic response and improve cardiac structure and function 179.…”

“…Some recent studies reported that serum miR-510 is increased in hypertension patients 175 and serum miR-7-5p and miR-26b-5p are elevated in the left ventricular hypertrophy (LVH) hypertensive patients compared with healthy individuals. 176 Moreover, let-7 levels in ECs and plasma from hypertension patients are higher than those from healthy controls. 177 However, levels of miR-9 and miR-126 in peripheral blood mononuclear cells (PBMCs) of hypertensive patients are reduced compared with healthy controls.…”

Non-coding RNA-linked epigenetic regulation in cardiac hypertrophy

“…For instance, elevated plasma levels of miR-29a are associated with hemolysis in patients with hypertrophic cardiomyopathy 107 . MiR-7-5p and miR-26b-5p are upregulated in the circulation of patients with left ventricular hypertensive compared with healthy subjects, which entail them as novel biomarkers for this disease 108 . Given the fact that ncRNA mimics or inhibitors can be easily synthesized and delivered to cells or organs with low toxicity 109 , ncRNAs will also be a promising and important modifiers to prevent cardiac hypertrophy.…”